Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.

http://www.wikidata.org/entity/Q36745002

about

Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B Dynamic comparison between Daan real-time PCR and Cobas TaqMan for quantification of HBV DNA levels in patients with CHB.Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis Impact of nucleos(t)ide analogue combination therapy on the estimated glomerular filtration rate in patients with chronic hepatitis B Comparison of the Efficacies and Safety of Combined Therapy between Telbivudine Plus Adefovir and Lamivudine Plus Adefovir in Patients with Hepatitis B Virus Infection in Real-World Practice HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.Comparison of telbivudine and entecavir on the change of off- treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients.Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents.Comprehensive review of telbivudine in pregnant women with chronic hepatitis B.Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis.Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection.Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease.Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model.DNA polymerase inhibitors for treating hepatitis B: a safety evaluation.Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy.Comparison of clinical efficacy and renal safety of telbivudine and entecavir in chronic hepatitis B patients receiving cytotoxic chemotherapy.Renal Function Improvement by Telbivudine in Liver Transplant Recipients with Chronic Kidney Disease.Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy.Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: A preliminary experience.Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine.Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B: a prospective cohort study in China.Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease.Significant renoprotective effect of telbivudine during preemptive antiviral therapy in advanced liver cancer patients receiving cisplatin-based chemotherapy: a case-control study.Telbivudine in liver transplant recipients: Renal protection does not overcome the risk of polyneuropathy and myopathy.Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors.Prevalence of renal abnormalities in chronic HBV infection: the HARPE study.Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy.Negative HBcAg in immunohistochemistry assay of liver biopsy is a predictive factor for the treatment of patients with nucleos(t)ide analogue therapy.Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update).Telbivudine therapy for gravidas with chronic hepatitis B infection and patients at risk of renal impairment.Improvement of telbivudine on renal function and massive proteinuria: A case report.Upgrade Combination Response Is Limited by Prolonged Nucelos(t)ide Analogue Therapy in HBeAg-positive Chronic Hepatitis B: A Real-life Study.Real World Experience of Telbivudine Versus Entecavir in Patients with Chronic Hepatitis B, Including Long-Term Outcomes after Treatment Modification.Progression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA

P2860

Q26864647-FB321B5C-15A3-4E28-B3B5-655432E126E7 Q30391932-1610FA9A-2FDA-492C-B196-BE9893286214 Q34726155-C5198289-8E63-4955-8CD6-F0D8D41203C0 Q35094389-9043082B-F8DF-4EF5-B53C-042B06933F81 Q36008792-68918455-7EF1-4098-9F7E-FF7343390483 Q36151245-E2813227-CA71-4194-978A-87C78686089F Q36180446-C88D00E4-6AED-476F-B744-70F6549C9DCB Q36255419-EB1F4796-FD60-4149-84D7-1E00880AFB33 Q36264219-26396337-5976-4677-9984-21642F963B10 Q36445048-FB06C132-F9E0-4481-982E-0C206A060495 Q36727510-732A6F67-9259-48DD-840F-FCE7ECD7E2D9 Q37229851-F2CEDEF9-1B73-41D5-A836-4BB37D5DE6BE Q37314031-7EB895E5-9706-47F2-9FE2-1D14733D83F0 Q37335661-6CC2858D-02F9-489F-8722-D4D5F3518EFE Q37421489-05D0BD97-7840-4076-979F-49AFEDB66B4B Q38168296-B6FE8988-FC72-4EA5-9ECF-C8ECAF0596E7 Q38295850-3813DCDE-00F1-4C46-8731-CA52C0D04D6E Q38559455-7C69875D-1A25-47A4-BB85-EB34CE12FA58 Q38692333-CE058482-9313-4455-AA29-E378234C1B5A Q39121074-BFE4753B-4D9F-4153-8F81-6A7CD66239AA Q39611116-2F1F62A5-C54B-4683-BE3D-A03C3B479E4F Q39846153-F1353EB4-BA9A-446B-9B73-338A2A9107E1 Q40051822-744EFC7A-19AE-4B85-B06A-4EEB88C8DC6B Q40101977-EAEFA026-DA58-46DE-95DB-B0F38661E00B Q40410635-B8FDD594-9BED-4948-8DDE-CD21A1EF75F5 Q40910330-C45507EF-3CD1-404C-845B-5D4B9065D43D Q41658570-3366C67C-70E4-44CD-B03A-BDC80D6CC40B Q41668771-E3343C38-70A0-466B-9008-21A8230B8C51 Q41715901-D2A2C4E9-A898-46C8-8BF4-5CAE5B0DC7B0 Q42150477-D9686756-C7D4-414D-9B8A-58C0263CAAD3 Q42199411-684705C0-6C52-4491-B32C-DF91786F3577 Q42238746-E70424D2-E00E-47A0-B55D-F246AFF4D54B Q42248312-C8B347BD-B828-4BBA-934D-9093EC3E6115 Q46191895-185D0B90-3C52-4D51-9437-06CD5AC25652 Q47142488-7453253B-7357-4E21-BA81-DD8BF2789C3D Q47596434-B834240C-E303-4C3E-8B11-E8883A603597 Q47596497-7C61F085-A9BF-4B0D-84FE-2B3457F5B569 Q52632458-83F3098C-5100-4C93-AAE5-AD530D9569EE Q55034780-1719B753-6172-4C4D-B9EA-128710F3974C Q57491223-D3A484BC-ABF7-4FD8-9EAF-735396F75AC4

P2860

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B.

http://www.wikidata.org/entity/Q36745002

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Efficacy and safety of continu ...... ents with chronic hepatitis B.

@ast

Efficacy and safety of continu ...... ents with chronic hepatitis B.

@en

type

label

Efficacy and safety of continu ...... ents with chronic hepatitis B.

@ast

Efficacy and safety of continu ...... ents with chronic hepatitis B.

@en

prefLabel

Efficacy and safety of continu ...... ents with chronic hepatitis B.

@ast

Efficacy and safety of continu ...... ents with chronic hepatitis B.

@en

P1433

Q36745002-86C2415E-7129-437C-9B49-C516576765ED

P1476

Q36745002-55B805E3-B513-4C44-ADF7-D3188A006D81

P2093

Q36745002-0807FAD3-86EE-4F58-BB35-1C1118586DA2

Q36745002-0DD9D60A-6825-47A0-B6A2-CA60D0A01909

Q36745002-256C1A5C-D144-49C6-9791-02760704BBED

Q36745002-320EB827-7AC9-44F7-BE37-C24A11797799

Q36745002-42B2A34A-40F9-45A9-83D0-9FCDD74ECDBC

Q36745002-531774E7-AD76-444D-91D8-BDC4E0576C47

Q36745002-5571B837-86D3-4D8E-A1F7-1494E1504577

Q36745002-A4D8F6A7-04D4-4389-8BB1-D6D58ECFAAB2

Q36745002-B9E3704C-1A68-414F-B6B8-9611734EC20A

Q36745002-C348ACB3-3AAE-46DE-A029-22A96FB892CA

P2860

Q36745002-1DAF3150-3076-463A-B5ED-6C9B07D059B4

Q36745002-2CDF8EFD-F620-4B49-AF74-B2C2E28C8612

Q36745002-2ED61EBD-5769-4778-A2C5-D954137BF9A7

Q36745002-2F04ED26-5326-4E07-89AD-ED165D582834

Q36745002-2FA33020-7E82-42F6-A8DF-7476CD2B1AE6

Q36745002-349BDF9A-3182-4706-AC71-E9EC0BDE7ECD

Q36745002-39297BC6-3225-4D54-A17F-6CD34727C17C

Q36745002-3D85F70A-9E68-47CD-9A00-AC347A14C704

Q36745002-43F6D323-2DF8-4C4C-9996-C9FFE7CB9EFD

Q36745002-76AAB4F6-8430-454F-8511-8C7BFEB33F0F

P304

Q36745002-D9E37C23-62A4-497F-9A85-D1D47EEC18DC

P31

Q36745002-7E117794-6DB2-496E-9091-74D685340801

P356

Q36745002-2B48D385-2ADB-4BBA-9066-F4D8EF20554F

P433

Q36745002-77F07AF8-4749-45B7-A500-F89C9E667077

P478

Q36745002-DC512761-170D-4C79-8666-B42F7B6FAC59

P50

Q36745002-28567082-4488-47AA-B79F-15E70C6CA50D

P577

Q36745002-E72984DF-DCDF-4F86-9091-76C6FEFDB8D9

P5875

Q36745002-01615E0B-2C4D-4972-9582-B65CDB630166

P698

Q36745002-1CC83510-A151-4400-A9D0-AACB863926CD

P932

Q36745002-71EE5E78-605F-48F4-9326-B708ECD028A9

P356

P1433

Journal of Viral Hepatitis

P1476

Efficacy and safety of continu ...... ients with chronic hepatitis B

@en

P2093

A Trylesinski

http://www.w3.org/2001/XMLSchema#string

E J Gane

http://www.w3.org/2001/XMLSchema#string

H L Y Chan

http://www.w3.org/2001/XMLSchema#string

J Hou

http://www.w3.org/2001/XMLSchema#string

J Jia

http://www.w3.org/2001/XMLSchema#string

J Niu

http://www.w3.org/2001/XMLSchema#string

M Wan

http://www.w3.org/2001/XMLSchema#string

N V Naoumov

http://www.w3.org/2001/XMLSchema#string

S Thongsawat

http://www.w3.org/2001/XMLSchema#string

W Bao

http://www.w3.org/2001/XMLSchema#string

P2860

Telbivudine versus lamivudine in patients with chronic hepatitis B

A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

Chronic hepatitis B: update 2009

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update.

Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B.

P304

e37-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JVH.12025

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

George Papatheodoridis

P577

2012-12-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236046405

http://www.w3.org/2001/XMLSchema#string

P698

23490388

http://www.w3.org/2001/XMLSchema#string

P932

3618368

http://www.w3.org/2001/XMLSchema#string